and gilead fractionally higher developing a small molecule pill treating diseases.d from the conference in san francisco, where jillian has been speaking with leaders in the obesity space. >> that's right, this year it's not just about weight loss anymore. we talked to two up-and-comers about how the appetite is already changing. and structure therapeutics ceo ray stevens sees pills as one way to reach millions more people than you can with inject ibles. everybody keeps trying to get the biggest number. it's really about the patient experience. so i think first, obviously you have to have efficacy, you have to have weight loss. but tollerable erating it is ju important and another category we think is important is accessibility. >> squee land's ceo says it is resonating with prospective pharma partners. >> if you get into this space, you want to get into a space where you have two giants that are dominating, would you rather invest in what looks to be, you can say, a standalone new category with the potential to be a foundational therapy. it's super exciting to come

>> gilead science is going into 2025 in a strong position.d and public health is this new hiv prevention medicine. incredibly the first large trial it showed it was 100 % effective at preventing hiv in participants in the trial with only two shots a year. it's hard to overstate the impact this will have on global public health. it will change the face of hiv. we are ready. we filed with the fda. we expect approval as early as a summer and have programs in developed world and eveloping world to get this medicine to the people it can benefit for. >> you mentioned the impact on global health and what you've done. the plan to make it available in some low, middle income families through generics authorization. critics say it's not enough and want to see more from you. how did you come up with that plan and you feel it's enough to address the need out there ? >> this is a groundbreaking medicine. we are approaching our access programs in an unprecedented way. immediately after we saw these results with the community and public health officials, we

there is a company called gilead science. some of you may have heard about this. it is an american company manufacturing pharmaceuticals in ireland, in a tax haven. they have the hep c cure. it is something that affects veterans more than any population. they come back and they are infected by hepatitis c and many others. the cost of producing that drug is one dollar a pill. they charge $1000 -- $1000 per pill. and we do not have the ability to negotiate that today. we have got to fix the doughnut hole. we've got to get rid of the cadillac tax. and we have to make sure that the fraud and abuse that is in their ash over $200 billion worth of unnecessary medical procedures are ordered today, and they are not stopped. there is a bipartisan way to do this, and we've got to do it. >> thank you. >> ok, the next question will go to ms. throne-holst. >> i feel compelled to say this was on my list when i sat down. it seems appropriate now. it is a proposal to prevent people on the government's terrorist watch list to prevent -- watch list to buy firearms. do you support th